DURECT (NASDAQ:DRRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of DURECT (NASDAQ:DRRXFree Report) in a research note issued to investors on Tuesday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating on shares of DURECT in a research note on Thursday, November 14th.

Check Out Our Latest Stock Analysis on DRRX

DURECT Price Performance

DRRX stock opened at $0.83 on Tuesday. The company’s 50 day simple moving average is $0.92 and its 200-day simple moving average is $1.23. The firm has a market capitalization of $25.83 million, a PE ratio of -1.36 and a beta of 0.94. DURECT has a 12 month low of $0.64 and a 12 month high of $1.88.

Hedge Funds Weigh In On DURECT

A hedge fund recently raised its stake in DURECT stock. Geode Capital Management LLC boosted its position in shares of DURECT Co. (NASDAQ:DRRXFree Report) by 4.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 319,905 shares of the specialty pharmaceutical company’s stock after purchasing an additional 14,658 shares during the period. Geode Capital Management LLC owned approximately 1.03% of DURECT worth $429,000 at the end of the most recent reporting period. 28.03% of the stock is currently owned by institutional investors.

About DURECT

(Get Free Report)

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.

Read More

Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.